Bifeprunox Mesylate
| Code | Size | Price |
|---|
| TAR-T26807-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T26807-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T26807-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Bifeprunox is a partial dopamine and serotonin agonist potentially for the treatment of schizophrenia. Bifeprunox suppresses in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation. Bifeprunox influences nicotine-seeking behaviour in response to drug-associated stimuli in rats.
CAS:
350992-13-1
Formula:
C25H27N3O5S
Molecular Weight:
481.57
Purity:
0.98
SMILES:
CS(O)(=O)=O.O=c1[nH]c2cccc(N3CCN(Cc4cccc(c4)-c4ccccc4)CC3)c2o1
References
1. Chattopadhyay A, Frey S, Green G, Harkness A, McDermott A, Yates A. Bifeprunox vs Placebo for Schizophrenia. Schizophr Bull. 2016 Jul;42(4):881-2. doi: 10.1093/schbul/sbw048. Epub 2016 May 6. PubMed PMID: 27153863; PubMed Central PMCID: PMC4903068.
2. De Santis M, Pan B, Lian J, Huang XF, Deng C. Different effects of bifeprunox, aripiprazole, and haloperidol on body weight gain, food and water intake, and locomotor activity in rats. Pharmacol Biochem Behav. 2014 Sep;124:167-73. doi: 10.1016/j.pbb.2014.06.004. Epub 2014 Jun 13. PubMed PMID: 24933333.
3. Di Clemente A, Franchi C, Orr? A, Arnt J, Cervo L. Bifeprunox: a partial agonist at dopamine D2 and serotonin 1A receptors, influences nicotine-seeking behaviour in response to drug-associated stimuli in rats. Addict Biol. 2012 Mar;17(2):274-86. doi: 10.1111/j.1369-1600.2011.00319.x. Epub 2011 Apr 26. PubMed PMID: 21521422.
4. Spiros A, Carr R, Geerts H. Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse. Neuropsychiatr Dis Treat. 2010 Sep 7;6:589-603. doi: 10.2147/NDT.S12460. PubMed PMID: 20856922; PubMed Central PMCID: PMC2938308.